阿卡波糖对新诊断糖耐量受损的急性冠脉综合征患者长期预后的影响
Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance.
作者信息
Yun Peng, Du Ai-ming, Chen Xue-jun, Liu Jing-cheng, Xiao Hu
机构信息
Department of Internal Medicine, School of Clinical Medicine, Yangtze University, Jingzhou, Hubei 434000, China.
Department of Cardiology, Central Hospital of Jingzhou City, Hubei 434001, China.
出版信息
J Diabetes Res. 2016;2016:1602083. doi: 10.1155/2016/1602083. Epub 2015 Dec 6.
OBJECTIVE
To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT).
METHODOLOGY
135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day, n = 67) or control group (no acarbose, n = 68). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed.
RESULTS
During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%, P < 0.05); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm, P < 0.05).
CONCLUSIONS
Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.
目的
探讨阿卡波糖治疗对合并新诊断糖耐量受损（IGT）的急性冠脉综合征（ACS）患者长期预后的影响。
方法
135例因ACS住院且新诊断为IGT的患者被随机分为阿卡波糖组（150毫克/天，n = 67）和对照组（未用阿卡波糖，n = 68）。每组所有病例均给予相同的基础治疗。平均随访2.3年。对主要不良心血管事件（MACE）的发生率和颈动脉内膜中层厚度（CIMT）进行统计学分析。
结果
在平均2.3年的随访期间，阿卡波糖组复发性MACE的风险与对照组相比显著降低（26.67%对46.88%，P < 0.05）；同时，CIMT增厚明显慢于对照组（（1.28 ± 0.42）毫米对（1.51 ± 0.64）毫米，P < 0.05）。
结论
阿卡波糖可有效降低新诊断IGT的ACS患者发生MACE的风险，同时延缓颈动脉内膜中层厚度的进展。
Zotero 插件